![Healthcare worker working at office](https://robbinsllp.com/wp-content/uploads/2021/06/healthcare-worker-working-at-office-300x200.jpg)
Investigation of Clover Health Investments
Clover Health Investment, Corp. (CLOV) Misled Shareholders Ahead of Going Public On October 6, 2020, the Company issued a press release announcing plans to become a publicly traded company
Clover Health Investment, Corp. (CLOV) Misled Shareholders Ahead of Going Public On October 6, 2020, the Company issued a press release announcing plans to become a publicly traded company
Romeo Power, Inc. (RMO, RMO.WT) Made Misstatements Regarding its Ability to Meet Demand On October 5, 2020, RMG Acquisition Corp., a special purpose acquisition company, announced a definitive agreement
ChemoCentryx, Inc. (CCXI) Misled Investors Regarding the Company’s Concerns for User Safety After the market closed on November 25, 2019, ChemoCentryx, Inc. (CCXI) announced “Positive Topline Data from Pivotal Phase
BlueCity Holdings Limited (BLCT) Misled Investors Regarding the Company’s Capability for Sustainable Growth According to the complaint, BlueCity conducted its IPO on July 8, 2020, issuing 5.3 million shares of
LifeMD, Inc. (LFMD) Misled Investors Regarding its Business Operations Throughout the class period, defendants made false and/or misleading statements regarding its business. Specifically, defendants failed to disclose that: (1) many
GoodRx Holdings, Inc. (GDRX) Misled Shareholders Regarding its Business Prospects Defendants timed the Company’s initial public offering (“IPO”) to happen just before Amazon.com, Inc. announced its online pharmaceutical business
Lordstown Motor Corporation (RIDE) Misled Investors About its Endurance Orders and Production Capabilities On August 1, 2020, Lordstown announced it had entered into a merger agreement with DiamondPeak Holdings Corp,
3D Systems Corp. (DDD) Lacked Proper Internal Controls Over Financial Reporting Throughout the class period, 3D Systems attested to the accuracy of its financial reporting and disclosure controls and
Acadia Pharmaceuticals Inc. (ACAD) Misled Shareholders Regarding the Viability of Pimavanserin for Dementia-Related Psychosis In April 2016, the FDA approved pimavanserin for the treatment of hallucinations and delusions associated
Attorney Advertising. Past results do not guarantee a similar outcome.
5060 Shoreham Pl., Ste. 300 San Diego, CA 92122
Disclaimer | Site Map | Privacy Policy
© 2024 – Robbins LLP
Stock Watch members receive free investment monitoring and notifications.